Single-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis

Xiao Li, Lili Yu, Liyuan Zhang, Wei Guo, Lixin Liu, Yunchuan Sun, Xuan Kan, Kai ZhangJournal of Cancer 2024 · DOI

TL;DR

This meta-analysis systematically reviews the long-term safety and efficacy of single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer. The findings suggest SFHDR-BT is generally well-tolerated with low toxicity rates, but its clinical benefit may be suboptimal, necessitating further high-quality prospective studies.

What Problem Does This Paper Address?

Prostate cancer treatment often involves radiation therapy, with brachytherapy offering a way to deliver higher doses directly to the tumor. While multi-fraction high-dose-rate brachytherapy (HDR-BT) is established, it comes with drawbacks like multiple hospital visits and extended recovery. Single-fraction HDR-BT (SFHDR-BT) emerged as a potentially more convenient alternative, but robust evidence on its long-term outcomes, especially safety and efficacy, has been lacking. This paper aims to fill that gap by systematically analyzing existing studies to provide a comprehensive overview of SFHDR-BT's performance.

Methods

The researchers conducted a systematic literature search across PubMed, Embase, and the Cochrane Library databases, adhering to PRISMA guidelines. They included studies on localized prostate cancer treated with SFHDR-BT, requiring a minimum follow-up of five years. The primary endpoints were safety (toxic effects like gastrointestinal and genitourinary issues, and sexual dysfunction) and efficacy (biochemical recurrence-free survival - bRFS, and overall survival - OS). They used proportion rates and 95% confidence intervals to measure effect. For quality assessment, they employed the Jadad scale for randomized controlled trials and the MINORS tool for non-randomized studies. Statistical analysis involved quantifying incidence rates, using forest plots, and assessing heterogeneity with Cochran's Q test and the Higgins I² statistic. Random-effects models were used when heterogeneity was significant, and fixed-effects models otherwise. Publication bias was assessed using Begg's funnel plot.

Datasets

This paper is a meta-analysis, meaning it synthesizes data from existing published studies. It does not introduce new datasets or benchmarks. The data is derived from eight eligible studies that met the inclusion criteria, encompassing a total of 552 patients.

Key Insights and Ideas

  • Convenience vs. Efficacy Trade-off: SFHDR-BT offers significant advantages in terms of treatment convenience (single session, shorter recovery) compared to multi-fraction HDR-BT. However, the results suggest this convenience might come at the cost of potentially "suboptimal clinical benefit," particularly regarding long-term biochemical control.
  • Low Acute Toxicity is Promising: The near-zero incidence of severe gastrointestinal toxicity and a low rate of severe genitourinary toxicity are encouraging findings, suggesting SFHDR-BT is a safe option in terms of immediate side effects.
  • Sexual Dysfunction Remains a Concern: While severe sexual dysfunction is relatively low (4%), the incidence of grade 2 sexual dysfunction is considerably higher (30%), with erectile dysfunction being the primary manifestation. This highlights the need for careful patient counseling and management of long-term quality of life.
  • bRFS is Moderate, OS is High: The meta-analysis shows a respectable but not outstanding long-term bRFS of 72%, while overall survival remains very high at 90%. This suggests SFHDR-BT can effectively manage the disease for many, but there's room for improvement in preventing recurrence.
  • Need for High-Quality Prospective Trials: The authors repeatedly emphasize the need for more rigorous, well-designed prospective studies to definitively confirm the safety and efficacy of SFHDR-BT, especially given the limitations of the current evidence base (e.g., inclusion of retrospective studies).

Key Results

  • Severe GI Toxicity: 0% cumulative incidence.
  • Severe GU Toxicity: 3% cumulative incidence (95% CI 1-5%).
  • Severe Sexual Dysfunction: 4% cumulative incidence (95% CI 1-7%).
  • Grade 2 Sexual Dysfunction: 30% cumulative incidence (95% CI 17-43%).
  • Long-term bRFS (5-6 years): 72% (95% CI 68-76%).
  • Long-term OS (5-6 years): 90% (95% CI 85-95%).
  • The study included 8 studies with a total of 552 patients, with a median follow-up of 71.3 months.

Limitations and Future Work

The authors acknowledge several limitations:

  • Inclusion of Retrospective Studies: The meta-analysis included a limited number of retrospective studies, which can introduce bias in data aggregation.
  • Limited Number of Studies: The overall number of studies and patients, while meeting inclusion criteria, is not vast, especially for long-term outcomes.
  • Patient Demographics: The cohort was predominantly Caucasian, limiting the generalizability of findings to diverse ethnic groups.

Future work should focus on:

  • High-Quality Prospective Studies: The most crucial recommendation is the need for more rigorously structured, prospective clinical trials to validate SFHDR-BT's safety and efficacy.
  • Optimizing Treatment Strategies: Further research could explore integrating local boosts with SFHDR-BT at the lesion site to address localized failures.
  • Understanding Tumor Heterogeneity: Investigating how tumor cell resistance mechanisms, like those in cancer stem cells, and tumor heterogeneity impact SFHDR-BT effectiveness is important.
  • Patient Selection: Refining patient selection criteria for SFHDR-BT is essential, particularly considering risk stratification.

Summary updated

Abstract

<b>Objective:</b> Although single-fraction high-dose-rate brachytherapy (SFHDR-BT) for localized prostate cancer has been attempted in clinical trials, there is currently a lack of relevant medical evidence. It is essential to conduct a systematic analysis of the long-term safety and efficacy of SFHDR-BT. <b>Materials and methods:</b> Comprehensive and systematic searches for eligible studies were performed in PubMed, Embase, and the Cochrane Library databases. The primary endpoints included safety and efficacy, represented by toxic effects, biochemical recurrence-free survival (bRFS) and overall survival (OS), respectively. The proportion rates were used as the effect measure for each study and were presented with corresponding 95% confidence intervals (CI). <b>Results:</b> Eight studies met the inclusion criteria for quantitative analysis, including 552 patients. The median follow-up was 71.3 months (60-72.8 months). The estimates of cumulative occurrence for severe gastrointestinal (GI) and genitourinary (GU) toxic effects were 0 and 3% (95% CI 1-5%), respectively. The pooled cumulative incidence of grade ≥ 3 sexual dysfunction occurrence was 4% (95% CI 1-7%). The estimate of long term bRFS was 72% (95% CI 68-76%) and 90% (95% CI 85-95%) for long term OS. <b>Conclusion:</b> In general, SFHDR-BT is well tolerated and associated with suboptimal clinical benefit in patients with localized prostate cancer. High-quality prospective studies of SFHDR-BT are necessary to verify its safety and efficacy.
BibTeX
@article{li2024single,
  author = {Xiao Li and Lili Yu and Liyuan Zhang and Wei Guo and Lixin Liu and Yunchuan Sun and Xuan Kan and Kai Zhang},
  title = {{Single-fraction high-dose-rate brachytherapy as monotherapy for localized prostate cancer: long-term follow-up study based on meta-analysis}},
  journal = {Journal of Cancer},
  year = {2024},
  doi = {10.7150/jca.104279},
}
Figure